[go: up one dir, main page]

WO2004003564A3 - Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases - Google Patents

Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases Download PDF

Info

Publication number
WO2004003564A3
WO2004003564A3 PCT/EP2003/006748 EP0306748W WO2004003564A3 WO 2004003564 A3 WO2004003564 A3 WO 2004003564A3 EP 0306748 W EP0306748 W EP 0306748W WO 2004003564 A3 WO2004003564 A3 WO 2004003564A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
tumour
tumours
same
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006748
Other languages
German (de)
French (fr)
Other versions
WO2004003564A2 (en
Inventor
Stephanie Lamer
Marie-Laure Fogeron
Hermann Lage
Udo Kellner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROPROTEOME AG
Original Assignee
EUROPROTEOME AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROPROTEOME AG filed Critical EUROPROTEOME AG
Priority to AU2003246592A priority Critical patent/AU2003246592A1/en
Publication of WO2004003564A2 publication Critical patent/WO2004003564A2/en
Anticipated expiration legal-status Critical
Publication of WO2004003564A3 publication Critical patent/WO2004003564A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/24—Extraction; Separation; Purification by electrochemical means
    • C07K1/26—Electrophoresis
    • C07K1/28—Isoelectric focusing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention relates to the use of the type II membrane protein NP 055070 (respectively Swiss-Prot number), NHP2-type protein 1 P55769, pre-mRNA cleavage factor Im (25kD) NP008937, Lysyl-tRNA synthetase Q15046, UNR-interacting protein Q9Y3F4, nucleic transport factor 2 P13662, erythrocyte phosphatase1 isoenzyme F P24666, Prefoldin sub-unit 2 Q9UHV9, heterogeneous nuclear ribonucleoprotein C1/C2 P07910, transitional endoplasmic reticulum-ATPase P55072, bifunctional methylenetetrahydrofolic acid dehydrogenase P13995, 47 kDa heat-shock protein precursor P29043, ubiquinol-cytochrome C reductase complex core protein P31930, the fragments thereof, detector substances targeting the same, and/or nucleic acids coding for the same, for producing a means for diagnosing tumours and for the prophylactic or therapeutic treatment of tumours.
PCT/EP2003/006748 2002-06-26 2003-06-26 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases Ceased WO2004003564A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003246592A AU2003246592A1 (en) 2002-06-26 2003-06-26 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10229386 2002-06-26
DE10229386.4 2002-06-26

Publications (2)

Publication Number Publication Date
WO2004003564A2 WO2004003564A2 (en) 2004-01-08
WO2004003564A3 true WO2004003564A3 (en) 2004-12-29

Family

ID=29796039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006748 Ceased WO2004003564A2 (en) 2002-06-26 2003-06-26 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases

Country Status (2)

Country Link
AU (1) AU2003246592A1 (en)
WO (1) WO2004003564A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507039A8 (en) 2004-01-22 2018-12-18 Univ Miami composition, methods of treating a cancer patient, and inhibiting angiogenesis in a tumor, and
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
JP6058263B2 (en) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー Methods and uses for inducing apoptosis in cancer cells
AU2008360729A1 (en) * 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
MX357528B (en) 2009-05-11 2018-07-13 Berg Llc METHODS FOR THE TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC EXCHANGERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES OR ENVIRONMENTAL INFLUENCES.
NZ720022A (en) 2010-03-12 2018-07-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CN103608323B (en) 2011-04-04 2016-08-17 博格有限责任公司 The method for the treatment of central nerve neuroma
MX369543B (en) 2011-06-17 2019-11-12 Berg Llc Inhalable pharmaceutical compositions.
CA2909094C (en) 2013-04-08 2023-06-27 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies
MX381399B (en) 2013-09-04 2025-03-12 Berg Llc COENZYME Q10 FORMULATIONS AND METHODS OF USE.
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM JINA ET AL: "Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins.", ELECTROPHORESIS, vol. 23, no. 24, December 2002 (2002-12-01), pages 4142 - 4156, XP002267151, ISSN: 0173-0835 (ISSN print) *
POON TERENCE C W ET AL: "Proteome analysis and its impact on the discovery of serological tumor markers", CLINICA CHIMICA ACTA, vol. 313, no. 1-2, November 2001 (2001-11-01), pages 231 - 239, XP002269361, ISSN: 0009-8981 *
SIMPSON RICHARD J ET AL: "Cancer proteomics: From signaling networks to tumor markers", TRENDS IN BIOTECHNOLOGY, vol. 19, no. 10 Supplement, 2001, pages S40 - S48, XP002269362, ISSN: 0167-7799 *

Also Published As

Publication number Publication date
AU2003246592A1 (en) 2004-01-19
WO2004003564A2 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
WO2004003564A3 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
AU7240096A (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001096388A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2740100A (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2003076631A3 (en) Genetic products differentially expressed in tumors and use thereof
WO2002078526A3 (en) Cancer-testis antigens
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2002051994A8 (en) Polypeptides
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
Fang et al. Expression of PTEN‐long mediated by CRISPR/Cas9 can repress U87 cell proliferation
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
NO20011394L (en) Mammoglobin, a secreted breast-specific breast cancer protein
IL207012A (en) Pharmaceutical composition comprising sgp28 and a vaccine composition for the treatment of a cancer expressing sgp28
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
WO2004013631A3 (en) Compositions and methods for diagnosis and therapy of cancer
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO2002002772A3 (en) Human extracellular matrix (ecm)-related tumor marker
WO2003018629A8 (en) Cage antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP